VIDEO: Ongoing trial examining olaparib, palbociclib and fulvestrant in BC subset
Click Here to Manage Email Alerts
In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, spoke with Healio about the ongoing HOPE trial.
The trial was presented at this year’s San Antonio Breast Cancer Symposium.
“HOPE stands for harnessing olaparib, palbociclib and endocrine therapy,” Shah said, adding that it is a phase 1 and phase 2 clinical trial.
The trial is assessing the combination of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza, AstraZeneca), the CDK4/6 inhibitor palbociclib (Ibrance, Pfizer), and the selective estrogen receptor degrader fulvestrant (Faslodex, AstraZeneca) among patients with breast cancer who have metastatic BRCA1 or BRCA2 mutations and hormone receptor signaling.
Shah said HOPE is a phase 1 trial because “this combination of drugs has never been evaluated before altogether, and we do have to be cautious, given the potential for overlapping toxicity of the olaparib and the palbociclib, which are two drugs that are known to potentially result in cytopenia.”
According to Shah, the goals of the trial are to evaluate the safety and efficacy of this drug combination and to complete “exploratory scientific analyses” with tumor tissues and blood samples from participants.“Within those studies, we want to better understand the biological basis for patients’ responses and resistance to treatment, and we also want to understand — separate from the therapeutic part of this clinical trial —the immunogenicity of BRCA-associated tumors.”
Reference:
Torres A, et al. Abstract OT2-18-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about
Click Here to Manage Email Alerts